Joshua Bauer
Faculty Member
Last active: 6/20/2014

  1. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL (2014) Cancer Discov 4(2): 232-45
    › Primary publication · 24356096 (PubMed) · PMC3946308 (PubMed Central)
  2. Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, Shyr Y (2013) Biomed Res Int : 915636
    › Primary publication · 24303503 (PubMed) · PMC3835197 (PubMed Central)
  3. A novel reporter system for molecular imaging and high-throughput screening of anticancer drugs. Xie J, Wang C, Virostko J, Manning HC, Pham W, Bauer J, Gore JC (2013) Chembiochem 14(12): 1494-503
    › Citation · 23881799 (PubMed) · PMC3819221 (PubMed Central)
  4. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA (2012) Cancer Inform : 147-56
    › Citation · 22872785 (PubMed) · PMC3412597 (PubMed Central)
  5. Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives. Ye F, Bauer JA, Pietenpol JA, Shyr Y (2012) BMC Genomics : S3
    › Citation · 23281588 (PubMed) · PMC3535706 (PubMed Central)
  6. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) J Clin Invest 121(7): 2750-67
    › Citation · 21633166 (PubMed) · PMC3127435 (PubMed Central)
  7. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA (2010) Breast Cancer Res 12(3): R41
    › Citation · 20576088 (PubMed) · PMC2917036 (PubMed Central)
  8. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA (2010) Clin Cancer Res 16(2): 681-90
    › Citation · 20068102 (PubMed) · PMC2892225 (PubMed Central)